



15 November 2023, 17.30 CET/16.30 GMT – 18.30 CET/17.30 GMT

The unknown diagnostic tool of MRD in pediatric AML

Presenter: Evangelia Antoniou

Expert: Michael Dworzak

Moderation: Andishe Attarbaschi

Programm details

- 17.15 Login open to audience
- 17.30 Welcome and introduction
- 17.32 Case presentation
- 17.47 Discussion with presenter and expert
- 18.02 Closing of presentation part/Providing additional background resources for the audience (publications, supporting material, etc.)
- 18:05 Completing the Questionnaire
- 18.35 Closing

Speaker profiles:

Evangelia Antoniou

Evangelia Antoniou is a fellow in paediatric hematology and oncology in university hospital of Essen. She graduated in the medical school of Aristotle university of Thessaloniki in 2017. Three years later she completed her experimental doctor thesis (dr.med.) in university of Essen. Her paediatric residency was completed in 2020. Acute myeloid leukemia (AML) consists her expertise field as she is a study doctor of the AML-BFM group since March 2020, taking part in the initial diagnosis and advisory of complicated cases around Germany. Minimal residual disease and remission status in paediatric AML consist the main points of her research. She has participated in the revision of the European standards of care for children with cancer (ESCALIER Project by SIOPE) and is also a co-author of the standard clinical practice recommendations for AML in children and adolescents for European reference network-paediatric cancer (ERN PAEDCAN).

Michael Dworzak

Univ.-Doz. Dr. Michael N. Dworzak (MD) is vice chair of the St. Anna Kinderspital in Vienna and Section Head of pediatric Oncology & Hematology. He is also chair of the Austrian pediatric AML-BFM clinical trial group, co-chair of the international AML-BFM study group and head of the Immunological Diagnostics laboratory at CCRI and Labdia Labordiagnostik GmbH. This laboratory unit is the national reference diagnostic center for immunophenotyping and flow cytometric MRD-evaluation for pediatric leukemia in Austria. He coordinates several international FLOW study groups and networks, including the iBFM FLOW network as well as the EuPAL FLOW Diagnostic Network. His major achievements include the establishment, clinical validation, and international dissemination of an innovative

EACCME® event reference number: #LEE/2023/01451

This event is eligible to apply for CME accreditation.

landmark-technology for response assessment in pediatric leukemias based on flow-cytometric minimal residual detection (FLOW-MRD). This eventually led to the integration of FLOW-MRD into clinical treatment protocols, which are applied by an intercontinental consortium for stratification of pediatric patients into relapse-risk-based treatment strata worldwide.